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Abstract
Background: Gut dysbiosis due to the adverse effects of antibiotics affects outcomes of lung infection. Previous
murine models relied on significant depletion of both gut and lung microbiota, rendering the analysis of immune
gut-lung cross-talk difficult.
Here, we study the effects of antibiotic-induced gut dysbiosis without lung dysbiosis on lung immunity and the
consequences on acute P. aeruginosa lung infection.
Methods: C57BL6 mice received 7 days oral vancomycin-colistin, followed by normal regimen or fecal microbial
transplant or Fms-related tyrosine kinase 3 ligand (Flt3-Ligand) over 2 days, and then intra-nasal P. aeruginosa strain
PAO1. Gut and lung microbiota were studied by next-generation sequencing, and lung infection outcomes were
studied at 24 h. Effects of vancomycin-colistin on underlying immunity and bone marrow progenitors were studied
in uninfected mice by flow cytometry in the lung, spleen, and bone marrow.
Results: Vancomycin-colistin administration induces widespread cellular immunosuppression in both the lung and
spleen, decreases circulating hematopoietic cytokine Flt3-Ligand, and depresses dendritic cell bone marrow
progenitors leading to worsening of P. aeruginosa lung infection outcomes (bacterial loads, lung injury, and
survival). Reversal of these effects by fecal microbial transplant shows that these alterations are related to gut
dysbiosis. Recombinant Flt3-Ligand reverses the effects of antibiotics on subsequent lung infection.
Conclusions: These results show that gut dysbiosis strongly impairs monocyte/dendritic progenitors and lung
immunity, worsening outcomes of P. aeruginosa lung infection. Treatment with a fecal microbial transplant or
immune stimulation by Flt3-Ligand both restore lung cellular responses to and outcomes of P. aeruginosa following
antibiotic-induced gut dysbiosis.
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Background
Recent advances in high-throughput bacterial sequen-
cing, allowing the large-scale study of the microbial
communities in humans and experimental models, led
to the study of the bacteria composing this flora,
since termed “microbiome” (or microbiota), as well as
their pathologic alterations, termed dysbiosis (or
dysbioses) [1]. Dysbiosis has been shown to be re-
sponsible for altered immune responses against patho-
gens [2]. The disruption of this microbiome-driven
immune homeostasis by antibiotics is considered a
mechanism for the deleterious effects of antibiotics
beyond the gut, such as predisposition to allergic lung
diseases [3]. Non-culture-based methods have shown
that the human microbiome includes bacterial com-
munities in body compartments other than the gut,
such as the lung. Therefore, the microbiome-driven
immune cross-talk between the gut and the lung, or
“gut-lung axis,” involves both gut and lung microbiota
[4]. However, these studies are based on models of
antibiotic-induced dysbiosis that rely on very broad-
spectrum antibiotics using associations of 4 to 5 anti-
biotics, many with systemic diffusion. Not only are
such models far from mirroring clinical situations,
but they also result in the form of dysbiosis with
significant overall depletion [5], and deplete both the
gut and lung microbiota [5, 6]. Therefore, it is diffi-
cult to decipher the respective roles of the lung and
gut microbiota on lung immunity and its impact on
lung infection.
We aim to determine the effects of antibiotic-
induced gut dysbiosis, without lung dysbiosis, on
outcomes in a non-lethal murine model of acute P.
aeruginosa lung infection and the underlying immune
alterations in order to manage side effects of
antibiotics.
Methods
Experimental model and study design
Gut dysbiosis was induced by treating 6–8-week-old
C57BL/6 mice with non-absorbable antibiotics (vanco-
mycin 0.5 g/L and colistin 0.15 g/L) administered in
drinking water ad libitum for 7 days; the control ani-
mals received untreated drinking water. In groups
treated with either immunomodulation (Flt3-Ligand) or
microbiota modulation (fecal microbiota transplant),
these interventions were performed on days 8 and 9 as
described below. At day 10, mice were anesthetized
briefly with inhaled sevoflurane, and acute sublethal
pneumonia was performed by intra-nasal instillation of
PAO1 at 5.106 CFU (or lethal pneumonia with PAO1 at
5.107 CFU in a subset of experiments). Control mice
were intra-nasally instilled with phosphate buffer saline
(PBS) instead of bacteria. For all experiments except
survival studies, mice were euthanized at 24 h after
PAO1 inoculation. Survival studies followed mice over
96 h, upon which surviving animals, if any, were eutha-
nized. The experimental design and study groups are
illustrated in Fig. 1.
All animal experiments were performed according to
national and local institutional committee for the use of
experimental animals’ guidelines and approval from the
national experimental ethics committee (APAFIS
number 7166).
Details concerning bacteria strain and culture, inocu-
lums, and animal provenance and husbandry can be
found in supplementary materials.
Study outcomes: lung injury, bacterial burdens, and
survival
In the abovementioned experimental study groups
(Fig. 1), the following outcomes were studied.
Alveolar-capillary barrier permeability was evaluated
by measuring fluorescein isothiocyanate (FITC)-la-
beled-albumin leakage from the vascular compartment
to the alveolar-interstitial compartment, expressed as
permeability index, as previously described [7]. Bron-
choalveolar lavage (BAL) was performed through
washing with a total of 1.5 mL PBS. Lung and spleen
bacterial burdens were studied by culturing sequential
dilutions of homogenates on agar plates. In survival
experiments, mice were followed up for up to 96 h.
Experimental details are provided in supplementary
materials.
Underlying mechanisms: gut and lung microbiota, lung
and spleen cellular responses, hematopoietic factors/
cytokines, and bone marrow progenitors
Lung and gut microbiota were studied by next-
generation sequencing through bacterial ribosomal 16S
gene sequencing on an Illumina Miseq (Illumina, San
Diego, CA). Detailed processes and bioinformatic ana-
lyses are provided in the supplemental materials.
Lung and spleen cellular responses and bone mar-
row progenitors were studied through flow cytometry
on organ homogenates on a LSR Fortessa (BD
Biosciences, San Jose CA) using appropriate cell-type
antibody panels. The gating strategy for neutrophils,
antigen-presenting cells, and the significant popula-
tions of lymphocytes in the lung are presented in
the supplemental figure 1.
Bone marrow progenitor cell populations were ana-
lyzed within the CD45+ phenotype with a BD LSR For-
tessa (BD Biosciences) using antibody panels gating
strategies and bioinformatic analyses according to the
targeted cell surface phenotypes (fully detailed in supple-
mentary materials).
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Modulation: fecal microbiota transplant and Flt-3L
administration
For fecal microbiota transplantation (FMT), fecal
pellets from untreated mice were suspended in PBS
(1 fecal pellet/1 mL of PBS). A total of 200 μL of the
resuspended pooled fecal material were administered
by oral gavage.
Flt3-Ligand treatment (Ozyme, Saint-Cyr L’Ecole,
France) was given by intraperitoneal injection over 2
consecutive days after antibiotic treatment was stopped,
for a total of 10 μg/mice.
Statistical analyses
Statistical analysis was carried out using Prism 5 soft-
ware (Graph-Pad Software, San Diego, CA). Values
are expressed as mean ± SD. Comparison between
groups was analyzed with nonparametric ANOVA
followed by Dunn’s multiple comparisons post hoc
tests. Survival curves were analyzed using the Log-
rank (Mantel-Cox) test. Significance was accepted at
p < 0.05.
Results
Prior oral non-absorbable antibiotic-induced gut
dysbiosis worsens outcomes of P. aeruginosa lung
infection
First, we assessed if oral non-absorbable antibiotics in-
duced gut dysbiosis. The gut microbiota from antibiotic-
treated mice before P. aeruginosa intra-nasal challenge
was altered compared to control (Fig. 2a). We also ob-
served an eradication of several bacterial families like
Muribaculaceae, Prevotellaceae, and Lachnospiraceae
and an expansion of Burkholderiaceae, Clostridiales, and
Lactobacillaceae. Eradication of several bacterial families
was associated with a decrease of gut microbiota diver-
sity (Fig. 2b). These modifications were observed with a
decrease of only one log of 16srDNA compared to un-
treated mice (supplemental figure 2). As expected, we
did not observe any modification of the effect of prior
oral non-absorbable on the composition and the diver-
sity of the lung microbiota before P. aeruginosa infection
(Fig. 2c, d).
Then, we assessed if prior oral non-absorbable anti-
biotic modified outcomes of P. aeruginosa acute pneu-
monia. Antibiotics administered in drinking water 7 days
before P. aeruginosa intra-nasal challenge were associ-
ated with worse infection outcomes (Fig. 3). P. aerugi-
nosa load increaseds by 103 CFU and 102 in the lung and
in the spleen, respectively, in antibiotic condition (Fig. 3a,
b). Lung injury was increased in antibiotic pre-treated
mice when compared to untreated controls (3.5 ± 1.4%
vs. 1.8 ± 1.1%, p < 0.05) (Fig. 3c). Finally, the survival of
antibiotic-treated mice survival decreased to 20% from
100% in untreated controls (p < 0.05) (Fig. 3d). Overall,
acute sublethal P. aeruginosa pneumonia became lethal
in antibiotic-treated mice compared to untreated
controls.
To demonstrate the causality of gut dysbiosis in worse
outcomes of P. aeruginosa-infected mice, we treated dys-
biosis using fecal microbiota transplant (FMT). Follow-
ing dysbiosis-inducing antibiotics, FMT also restored the
composition and the diversity of the gut microbiota
equivalent to controls (Fig. 2a, b) and did not modify the
composition and the diversity of the lung microbiota
(Fig. 2c, d). Of note, P. aeruginosa intra-nasal challenge
did not further modify the gut microbiota shift observed
in antibiotic-treated mice (supplemental figure 3). As ex-
pected, P. aeruginosa intra-nasal challenge resulted in a
Fig. 1 Experimental design and study groups
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lung microbiota dominated by Pseudomonadaceae (sup-
plemental figure 3). Finally, FMT before P. aeruginosa
inoculation restored pneumonia outcomes to those of
control mice (Fig. 3a–d).
Oral non-absorbable antibiotic-induced gut dysbiosis
results in widespread lung and spleen immune
depression associated with altered myelopoiesis
Next, we assessed whether antibiotic-induced gut
dysbiosis had any effects on baseline lung and circulating
cellular immune profiles as a potential mechanism
underlying worse outcomes following P. aeruginosa lung
infection.
Cell population analysis in lung tissue showed that
antibiotics resulted in widespread depression of lung
cellular immunity with a significant decrease in macro-
phages, cDC2, inflammatory monocytes, neutrophils, γδ-
T cells, NKs, and iNKT cells (Fig. 4a). FMT restored
most of these alterations in macrophages, cDC2, inflam-
matory monocytes, neutrophils, and iNKT cells (Fig. 4a),
establishing a significant role of antibiotic-induced gut
dysbiosis in this widespread depression of the lung
immune response. Likewise, antibiotics resulted in wide-
spread depression of most studied spleen immune cell
populations (p < 0.05 except for a trend in NK cells), also
partially restored by FMT (Fig. 4b).
Because the spleen is a hematopoietic organ in mice,
we sought to determine the effects of antibiotics on im-
mune cell hematopoietic factors, specifically on circulat-
ing serum levels of GM-CSF, M-CSF, and Flt3-Ligand
(Fig. 5a). While circulating levels of GM-CSF were at the
detection threshold (1 pg/mL) and remained unaltered,
antibiotics induced a significant decrease in Flt3-Ligand,
and only a trend in M-CSF decrease. Given the known
role of Flt3-Ligand as a major hematopoietic stimulating
factor, mainly for monocyte and DC progenitors, we
studied the effects of antibiotics and FMT on bone mar-
row monocyte and DC progenitors (Fig. 5b and supple-
mental figure 5). We found that antibiotics were
associated with a significant decrease in bone marrow
progenitors specific to resident monocytes (MonoLy6C-)
and several specific to DCs (total pre-DCs, pre-DCs 1
and 2, and cCD2-biased pre-DCs). Among these, FMT
following antibiotics restored levels of pre-DCs 1. FMT
Fig. 2 Gut microbiota and lung infection by P. aeruginosa. a Bacterial family as percentages of sequenced 16S rDNA in the stool of uninfected
mice treated or not by oral vancomycin (VAN) and colistin (CST) or fecal microbiota transplant (FMT). b Alpha diversity (Shannon index) of
distinguishable taxa in sequenced stool samples. c Bacterial family as percentages of sequenced 16S rDNA in the lung of uninfected mice treated
or not by oral vancomycin (VAN) and colistin (CST) or fecal microbiota transplant (FMT). d Alpha diversity (Shannon index) of distinguishable taxa
in sequenced stool samples. For all microbiota experiments, there are 5 mice per group
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also stimulated the expansion of bone marrow progeni-
tors common to monocytes/macrophages/DCs (MDP),
common dendritic cell progenitors (CDP), and specific
to monocytes and macrophages (cMoPs). Our results
suggest that the effects of antibiotic-induced dysbiosis
on monocyte/macrophage and DC progenitors may be
involved in the widespread antibiotic-induced lung im-
mune depression associated with worse P. aeruginosa
lung infection outcomes.
Hematopoietic cytokine Flt3-L stimulates bone marrow
progenitor and lung immune cell expansion and restores
outcomes of P. aeruginosa lung infection following oral
non-absorbable antibiotics
Systemic Flt3-L following antibiotics stimulated the
expansion of several progenitors (MDPs, CDPs, and
cDC-1-biased pre-DCs) (Fig. 6a and supplemental figure
6). Flt3-Ligand administration partially restored or over-
stimulated the expansion of depressed alveolar macro-
phages, cDC2, inflammatory monocytes, neutrophils,
NK, and iNKT (Fig. 6b and supplemental figure 6).
Finally, the effects of Flt3-Ligand (Flt3-L) adminis-
tration following antibiotics on the outcomes of sub-
lethal P. aeruginosa lung infection were similar to
those of FMT. Thus, Flt3-L administration led to a
decrease permeability index in VAN/CST mice group
compared to VAN/CST + FLT-3 mice group (Fig. 6c).
Additionally, Flt3-L administration led to a decrease
of P. aeruginosa load in both lung and spleen in
VAN/CST mice group compared to VAN/CST + Flt-
3L mice group to a level similar to the controls
(Fig. 6d, e). Finally, Flt3-Ligand was also associated
with decreased mortality in a lethal P. aeruginosa
lung infection model, from 100 to 40% (p < 0.05) simi-
lar to the effects of FMT (Fig. 6f).
Discussion
Our results show that oral non-absorbable antibiotics in-
duce gut dysbiosis, without lung dysbiosis, leading to a
widely depressed lung immune cellular response respon-
sible for worse outcomes of subsequent P. aeruginosa
lung infection. These effects involve bone marrow
Fig. 3 Outcomes of lung infection by P. aeruginosa. a, b Lung and spleen bacterial loads and c alveolar-capillary barrier permeability measured
24-h after intra-nasal sublethal P. aeruginosa (PAO1), in mice previously treated or not (controls) with 7-day oral vancomycin/colistin (VAN/CST)
followed by fecal microbiota transplant (VAN/CST + FMT) or not. d 72-h survival of mice challenged with sublethal P. aeruginosa (PAO1) treated
or not (controls) with 7-day oral vancomycin/colistin (VAN/CST) followed by fecal microbiota transplant (VAN/CST + FMT) or not. For all
experiments, there are 5 mice per group, except for mortality, and 10 mice per group in duplicate; results are shown as mean ± SD; *p < 0.05
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progenitor depression and are susceptible to therapeutic
immunomodulation by the hematopoietic cytokine Flt3-
L as well as fecal microbial transplant.
Our study shares limitations inherent to the experi-
mental model. Ours is a murine model that does not
strictly mimic a clinical situation and cannot therefore
be extrapolated to clinical practice. However, animal
models allow studying complex interactions such as the
gut-bone marrow-lung axis without the added com-
plexities related to the heterogeneity of patients. Fur-
thermore, our choice of oral non-absorbable antibiotics
(vancomycin and colistin) while not representative of
antimicrobial therapies administered to intensive care
unit (ICU) patients, allowed us to differentiate the ef-
fects of antibiotics on the gut from the lung. Addition-
ally, oral vancomycin and colistin are components of
selective digestive decontamination (SDD), which is a
relevant ICU situation. Technical limitations to micro-
biota analysis were a limited number of animals that
was mitigated by very clear shifts and/or inversions ob-
served. Last, animals were not randomized to study
groups, while this may be a potential study bias; studied
mice are a standard breeding lineage from large batches
bred by an international supplier where breeding
schemes help minimize the risk of systematic differ-
ences in baseline characteristics.
The first description linking altered gut microbiota
and outcome of bacterial lung infection used germ-free
mice infected with Klebsiella pneumoniae [8]. Several
authors described afterward that the gut microbiota
protects against respiratory infection by Streptococcus
pneumoniae, K. pneumoniae, and P. aeruginosa [5, 6, 9].
However, these studies used very broad-spectrum anti-
biotic regimens, which lead to a significant depletion of
overall bacterial 16srDNA in the gut. We observed a re-
duction from 106 to 102 gene copies/ng DNA [5], which
is closer to “germ-free-like” models than to clinically
relevant antibiotic regimens. In comparison, our model’s
gut dysbiosis was mainly due to shifts in phyla, not to
extreme overall depletion. We observed depletion of
only 1 log copies 16 s rDNA (supplemental figure 3) ra-
ther than 4 log copies 16 s rDNA [5]. Therefore, our
data suggest that eradicating some phyla and/or expan-
sion of others is sufficient to alter the responses to lung
infection independently of significant/complete overall
gut microbiome depletion.
Conversely to lung dysbiosis associated with altered
outcomes like asthma [10], our treatment did not
Fig. 4 Effects of oral non-absorbable antibiotics on lung and spleen immune cell populations. a Flow cytometry of immune cells from lung
homogenates in mice treated or not (controls) with 7-day oral vancomycin/colistin (VAN/CST) followed by fecal microbiota transplant (VAN/CST +
FMT) or not. b Flow cytometry of immune cells from spleen homogenates in mice treated or not (controls) with 7-day oral vancomycin/colistin
(VAN/CST) followed by fecal microbiota transplant (VAN/CST + FMT) or not. For all experiments, group size is 5 mice per group; results are shown
as mean ± SD; *p < 0.05
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significantly modify the lung microbiota, suggesting other
links between the observed gut dysbiosis and lung out-
comes. Since we used non-absorbable oral antibiotics, this
treatment had no direct effect on the lung microbiota. In
contrast, this may have been the case in other dysbioses
induced by systemically diffusing antibiotics, as in the
study of Robak et al. in which lung microbiota depletion
was confirmed [5]. Therefore, lung dysbiosis is not a re-
quirement for the deleterious effects of prior antibiotics,
and lung dysbiosis may rather be another collateral dam-
age when antibiotics diffuse systemically to the lung.
In previous studies in which antibiotic-induced gut
dysbiosis was shown to worsen bacterial pneumonia
outcomes, the study of lung immune responses was fo-
cused in scope. Indeed, assessment of lung immunity
restricted to macrophages showed that macrophage
function was impaired consecutively to antibiotic-
induced gut dysbiosis and involved in worse outcomes
in an S. pneumoniae pneumonia model [9]. Likewise,
lung immunity assessment restricted to IgA-producing
cells found that IgA production was impaired in the
lung and involved in worse outcomes in a P. aeruginosa
pneumonia model [5].
We conducted a broader assessment of the immune
response after antibiotic-induced gut dysbiosis and ob-
served widespread lung cellular immune depression. Im-
mune depression included cells crucial to the clearance
of P. aeruginosa from the lung, such as alveolar macro-
phages, non-conventional lymphocytes, and neutrophils.
Bone marrow progenitors of monocytes and DC were
depressed and partially corrected by FMT, suggesting
the involvement of immune cell hematopoiesis. A link
between antibiotic-induced dysbiosis and depressed
hematopoiesis has been demonstrated. In a non-
infectious model [11] and in mice infected by Flaviviri-
dae [12].
Fig. 5 Effects of oral non-absorbable antibiotics on hematopoietic factors and bone marrow monocyte/dendritic cell progenitors. a ELISA of
hematopoietic factors in serum of mice treated or not (controls) with 7-day oral vancomycin/colistin (VAN/CST) followed by fecal microbiota
transplant (VAN/CST + FMT) or not. b Flow cytometry of monocyte/DC progenitors in the bone marrow in mice treated or not (controls) with 7-
day oral vancomycin/colistin (VAN/CST) followed by fecal microbiota transplant (VAN/CST + FMT) or not. For all experiments, group size is 5 mice
per group; results are shown as mean ± SD; *p < 0.05
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Fig. 6 (See legend on next page.)
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We found that FMS-like tyrosine kinase 3 ligand
(Flt3-Ligand) was significantly decreased by antibiotic-
induced gut dysbiosis and partially restored by FMT.
Flt3-Ligand is a cytokine that acts as a hematopoietic
growth factor for early progenitors through its recep-
tor, Flt3, in synergy with other cytokines [13]. When
administered after antibiotics, Flt3-L (a) restored or
stimulated the expansion of several monocytes and
dendritic cells (DC) bone marrow progenitors, (b) re-
stored or stimulated immune lung cell populations,
(c) restored outcomes of sublethal P. aeruginosa lung
infection, and (d) increased survival of lethal P. aeru-
ginosa lung infection. Flt3-Ligand promotes the gener-
ation of a primarily myeloid cell containing colonies.
Flt3-Ligand is essential to the generation of DC.
Furthermore, Flt3-Ligand transgenic mice show a
significant expansion of Flt3-positive cells and progen-
itors (myeloid cells, DCs, MPP, CMP, granulocyte-
macrophage progenitors, CLP, and EPLM progenitors)
[14]. Administration of human Flt3-Ligand into mice
increases DC-marker positive cells in the bone mar-
row, liver, Peyer’s patches, thymus, peritoneum, and
lung [15]. In a murine model of influenza A virus in-
fection, Beshara et al. showed that Flt3-L overexpres-
sion reduced the dissemination of S. pneumoniae
instilled into the lungs by enhancing bone marrow
cDC progenitors and restoring lung cDCs [16]. These
results suggest that its protective effect is not limited
to P. aeruginosa.
Interestingly, recombinant human Flt3-L (CDX-301,
Celldex Therapeutics, Hampton, NJ, USA) is currently
undergoing over 30 clinical trials to treat various malig-
nancies. Furthermore, given the FMT recent safety is-
sues [17], it is of particular interest that deleterious
effects of prior antibiotics on lung immunity may be
modulated beyond the gut microbiome.
Conclusion
Contrary to emerging controversial postulates [18], the
gut microbiota, independently from the lung microbiota,
might be crucial to developing an appropriate lung im-
mune response as suggested by our results restricted to
oral vancomycin-colistin and P. aeruginosa strain PAO1
in mice. In this specific murine model, treating
antibiotic-induced dysbiosis through FMT or treating
the associated lung immune depression through Flt3-
Ligand restores P. aeruginosa (PAO1 strain) lung infec-
tion outcomes in mice and may be potential directions
for translational research.
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Additional file 1 : Supplemental figure 1. Gating strategy for
neutrophils, antigen-presenting cells, and the significant populations of
lymphocytes in the lung. The percentages of natural killer (NK), invariant
NKT cells (iNKT), and T Lc with a TCRgd were determined. Among APC,
we identified alveolar macrophages (AM), inflammatory monocytes, pa-
trolling monocytes, interstitial macrophages (IM), and conventional den-
dritic cells (cDC)1 and 2.
Additional file 2 : Supplemental figure 2. Total bacterial 16SrDNA in
the stool. Mice (n = 5) were treated by oral vancomycin (VAN) and
colistin (CST) or not. Total 16srDNA expressed in relative quantity (fold-
decrease) between VAN/CST and untreated controls (reference = 1).
Additional file 3 : Supplemental figure 3. Bacterial family as
percentages of sequenced 16S rDNA in the lung and gut. Mice were
treated or not by oral vancomycin (VAN), and colistin (CST) followed or
not by fecal microbiota transplant (FMT) and infected or not by P.
aeruginosa PAO1 (n = 2 per group).
Additional file 4 : Supplemental figure 4. Effects of oral non-
absorbable antibiotics on lung and spleen immune cell populations. (A)
Flow cytometry of immune cells from lung homogenates in mice treated
or not (controls) with 7-days oral vancomycin/colistin (VAN/CST) followed
by fecal microbiota transplant (VAN/CST + FMT) or not. (B) Flow cytome-
try of immune cells from spleen homogenates in mice treated or not
(controls) with 7-days oral vancomycin/colistin (VAN/CST) followed by
fecal microbiota transplant (VAN/CST + FMT) or not. All experiments,
group size 5 mice per group, results are shown as mean ± SD; *: p < 0.05.
Additional file 5 : Supplemental figure 5. Effects of oral non-
absorbable antibiotics on hematopoietic factors and bone marrow mono-
cyte/dendritic cell progenitors. (A) ELISA of hematopoietic factors in
serum of mice treated or not (controls) with 7-days oral vancomycin/co-
listin (VAN/CST) followed by fecal microbiota transplant (VAN/CST + FMT)
or not, (B) Flow cytometry of monocyte/DC progenitors in the bone mar-
row in mice treated or not (controls) with 7-days oral vancomycin/colistin
(VAN/CST) followed by fecal microbiota transplant (VAN/CST + FMT) or
not. For all experiments, group size 5 mice per group; results are shown
as mean ± SD; *: p < 0.05.
Additional file 6 : Supplemental figure 6. Effects of Flt3-Ligand on
lung immune cell populations and on outcomes of lung infection. (A)
Flow cytometry of monocyte/DC progenitors in the bone marrow of
mice treated or not (controls) with 7-days oral vancomycin/colistin (VAN/
CST) followed by systemic Flt3-Ligand administration (VAN/CST + Flt3-L)
or not, (B) Flow cytometry of immune cells from lungs of mice with 7-
days oral vancomycin/colistin (VAN/CST) followed by systemic Flt3-Ligand
administration (VAN/CST + Flt3-L) or not. For all experiments, group size
5 mice per group; results are shown as mean ± SD; *: p < 0.05.
Additional file 7.
(See figure on previous page.)
Fig. 6 Effects of Flt3-Ligand on lung immune cell populations and on outcomes of lung infection. a Flow cytometry of monocyte/DC progenitors
in the bone marrow of mice treated or not (controls) with 7-day oral vancomycin/colistin (VAN/CST) followed by systemic Flt3-Ligand
administration (VAN/CST + Flt3-L) or not. b Flow cytometry of immune cells from lungs of mice with 7-day oral vancomycin/colistin (VAN/CST)
followed by systemic Flt3-Ligand administration (VAN/CST + Flt3-L) or not. c, d Lung and spleen bacterial counts and e alveolar-capillary barrier
permeability, measured in mice treated or not (controls) with 7-day oral vancomycin/colistin (VAN/CST) followed by systemic Flt3-Ligand
administration (VAN/CST + Flt3-L) or not. For all experiments, group size is 5 mice per group; results are shown as mean ± SD; *p < 0.05. e Survival
of mice after lethal P. aeruginosa pneumonia treated or not by FMT or Flt3-L; group size is 10 mice per group; *p < 0.05
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